首页> 外文OA文献 >Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients

【2h】

Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients

机译：Re：Cyp2D6基因型和三种毒素反应患有内分泌响应乳腺癌的绝经后妇女：乳房国际组1-98试验和RE：CYP2D6和UGT2B7基因型和制革治疗乳腺癌患者的复发风险

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
P. D. P. Pharoah; J. Abraham; C. Caldas;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients [J] . Paul D. P. Pharoah Jean Abraham and Carlos Caldas Journal of the National Cancer Institute . 2012,第16期

机译：Re：CYP2D6基因型和他莫昔芬对内分泌反应性乳腺癌的绝经后妇女的反应：国际乳腺癌组织1-98试验和Re：CYP2D6和UGT2B7基因型与他莫昔芬治疗的乳腺癌患者的复发风险
2. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients [J] . PharoahP.D.P., AbrahamJ., CaldasC. Journal of the National Cancer Institute . 2012,第16期

机译：Re：CYP2D6基因型和他莫昔芬反应对绝经后内分泌反应性乳腺癌妇女的影响：乳腺癌国际组1-98试验和Re：CYP2D6和UGT2B7基因型与他莫昔芬治疗的乳腺癌患者的复发风险
3. Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial [J] . Yusuke Nakamura Mark J. Ratain Nancy J. Cox Howard L. Mcleod Deanna L. Kroetz and David A. Flockhart Journal of the National Cancer Institute . 2012,第16期

机译：Re：CYP2D6基因型和他莫昔芬反应在绝经后妇女内分泌反应性乳腺癌中的应用：国际乳腺癌组织1-98试验
4. Study on the Efficacy Evaluation of Oral Sequential Tamoxifen in Postmenopausal Women with Hormone-dependent Breast Cancer [C] . Na Li, Yahua Sun, Sheng Zhao, International Conference on Life Sciences, Medicine, and Health . 2018

机译：激素依赖性乳腺癌后代妇女口腔序列儿毒素疗效评价研究
5. Codes, identities and pathologies in the construction of tamoxifen as a chemoprophylactic for breast cancer risk reduction in healthy women at high risk. [D] . Wooddell, Margaret J. 2004

机译：他莫昔芬作为化学预防剂在高风险健康女性中降低乳腺癌风险的化学预防措施中的代码，身份和病理。
6. CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial [O] . Meredith M. Regan, Brian Leyland-Jones, Mark Bouzyk, -1

机译：CYP2D6基因型和他莫昔芬反应在绝经后妇女的内分泌反应性乳腺癌：乳腺癌国际组1-98试验。
7. CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial [O] . Regan, Meredith M., Leyland-Jones, Brian, Bouzyk, Mark, 2017

机译：CYP2D6基因型和他莫昔芬反应在绝经后妇女的内分泌反应性乳腺癌：乳腺癌国际组1-98试验。

Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients

著录项

引文网络

相似文献

相关主题

期刊订阅